Edward Nash
Stock Analyst at Canaccord Genuity
(4.37)
# 322
Out of 4,931 analysts
85
Total ratings
49.32%
Success rate
20.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $420 → $428 | $342.29 | +25.04% | 10 | Aug 6, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $142 → $137 | $71.48 | +91.66% | 8 | Aug 1, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $28 | $9.05 | +209.39% | 1 | Jul 24, 2025 | |
| VRNA Verona Pharma | Downgrades: Hold | $107 | $105.40 | +1.52% | 10 | Jul 9, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $64 | $21.21 | +201.74% | 1 | Apr 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $16.91 | +177.94% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $0.53 | +1,588.56% | 2 | Feb 26, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.68 | +138.10% | 2 | Feb 10, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $50.44 | +44.73% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $36.00 | +147.22% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $14 | $2.36 | +493.22% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.08 | +640.74% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $3.64 | +449.45% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $3.21 | +149.22% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $5.57 | +205.21% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.08 | -3.85% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.37 | +13,038.69% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $27.83 | +194.65% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $2.45 | +3,165.31% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $13.45 | +256.88% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $6.27 | +10,266.83% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $420 → $428
Current: $342.29
Upside: +25.04%
Corcept Therapeutics
Aug 1, 2025
Maintains: Buy
Price Target: $142 → $137
Current: $71.48
Upside: +91.66%
Sagimet Biosciences
Jul 24, 2025
Initiates: Buy
Price Target: $28
Current: $9.05
Upside: +209.39%
Verona Pharma
Jul 9, 2025
Downgrades: Hold
Price Target: $107
Current: $105.40
Upside: +1.52%
Celldex Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $64
Current: $21.21
Upside: +201.74%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $16.91
Upside: +177.94%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.53
Upside: +1,588.56%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.68
Upside: +138.10%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $50.44
Upside: +44.73%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $36.00
Upside: +147.22%
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $2.36
Upside: +493.22%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.08
Upside: +640.74%
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $3.64
Upside: +449.45%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $3.21
Upside: +149.22%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $5.57
Upside: +205.21%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.08
Upside: -3.85%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.37
Upside: +13,038.69%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $27.83
Upside: +194.65%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $2.45
Upside: +3,165.31%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $13.45
Upside: +256.88%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $6.27
Upside: +10,266.83%